Error occured in EAN validator
BSTY.MC operates in the healthcare sector, specifically within biotechnology and medical research, focusing on pharmaceuticals and medical research activities.
Business. Error occured in EAN validator is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the BME (Madrid) exchange under the ticker symbol BSTY.MC. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Error occured in EAN validator is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the BME (Madrid) exchange under the ticker symbol BSTY.MC. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
BSTY.MC has a basic and diluted share count of 68,085,767, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
The company reported a negative EPS of -0.22 EUR and revenue of 2,524,590 EUR in the latest period, suggesting a lack of profitability and potential operational challenges. These figures fall below the typical performance metrics for the biotechnology and medical research industry, which usually emphasize strong R&D investment and high-growth revenue trajectories.
No specific segments or geographic exposure details are available in the provided data, making it difficult to assess revenue concentration or diversification. The absence of segmental data limits the ability to evaluate the company's exposure to different therapeutic areas or geographic markets.
The company's recent financial performance indicates a negative growth trajectory, with a significant drop in profitability. Without additional data on future revenue projections or strategic initiatives, it is challenging to determine the company's growth potential in the coming fiscal years.
The risk assessment highlights a low dilution risk, but the inability to assess liquidity risk raises concerns about the company's financial stability. The absence of balance-sheet data and going-concern language in the source documents suggests a lack of transparency or disclosure, which could be a red flag for investors.
No recent events, such as filings or transcripts, are provided in the data, which limits the ability to understand the company's current strategic direction or operational developments.
- BSTY.MC has a basic and diluted share count of 68,085,767, indicating no immediate dilution pressure.
- The company reported a negative EPS of -0.22 EUR and revenue of 2,524,590 EUR, suggesting operational challenges.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
- No recent events or strategic initiatives are disclosed, limiting visibility into the company's future direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €2.5M, −30,2% YoY; Operating income −206,6% YoY.
- ▍Revenue €2.5M, −30,2% YoY
- ▍Operating income −206,6% YoY
- ▍Net income −285,4% YoY
- ▍Free cash flow −138,6% YoY
- ▍Net margin -116.0%
Revenue €3.6M, +37,8% YoY; Operating income +253,5% YoY.
- ▍Revenue €3.6M, +37,8% YoY
- ▍Operating income +253,5% YoY
- ▍Net income +181,0% YoY
- ▍Free cash flow +294,3% YoY
- ▍Net margin 43.7%
Revenue €2.6M, −15,3% YoY; Operating income +16,6% YoY.
- ▍Revenue €2.6M, −15,3% YoY
- ▍Operating income +16,6% YoY
- ▍Net income +35,5% YoY
- ▍Free cash flow −16,2% YoY
- ▍Net margin -74.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Error occured in EAN validator Market data — financials · 2026-05-27
- Biotechnology Assets SA Market data — analyst estimates · 2026-05-27